Posted by Michael Wonder on 20 Oct 2016
Oncologists knock ICER's lung cancer cost-effectiveness review
20 October 2016 - Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for new medicines for patients with non-small-cell lung cancer, a group of oncologists is airing “serious concerns” about the organisation’s assessment techniques.
The oncologists have laid out principles that they believe should serve as the “start of a discussion” around building a value framework.
Published on the oncology news platform OBR, the editorial takes issue with a recent ICER report that concluded several medicines for patients with non-small-cell lung cancer would need deep discounts in order to be cost-effective. After reading the report, the docs say they're concerned about “ICER’s ability to interpret clinical evidence and reach conclusions on drug value that are scientific, comprehensive, and unbiased.”
